---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-037280"
form_type: "8-K"
ticker: "NUVL"
cik: "0001861560"
company_name: "Nuvalent, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-22T00:02:31.284537+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Nuvalent Q3 net loss $19.7M; NVL-520 shows proof-of-concept; $264.5M offering extends runway into H2 2025

## Summary
- Q3 net loss $19.7M ($0.41/sh); cash $240.1M; with $264.5M offering extends runway into H2 2025.
- NVL-520 Phase 1 data: no DLTs, activity in heavily pre-treated ROS1+ NSCLC including G2032R and brain metastases.
- NVL-655 (ALK inhibitor) enrollment in Phase 1 ALKOVE-1 trial progressing; new preclinical data shows activity against compound mutations.
- NVL-330 (HER2 exon 20) preclinical data demonstrates potency, selectivity, brain penetration; potential best-in-class.

## SEC filing metadata
- accession: 0001564590-22-037280
- form_type: 8-K
- ticker: NUVL
- cik: 0001861560
- company_name: Nuvalent, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861560/000156459022037280/0001564590-22-037280-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861560/000156459022037280/nuvl-8k_20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-037280
- JSON: https://secwatch.observer/filing/0001564590-22-037280.json
- Plain text: https://secwatch.observer/filing/0001564590-22-037280.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.